Cannabis sativa is a plant rich in more than 100 types of cannabinoids. Besides exogenous plant cannabinoids, mammalian endocannabinoids and synthetic cannabinoid analogues have been identified. Cannabinoid receptors type 1 (CB1) and type 2 (CB2) have been isolated and characterised from mammalian cells. Through cannabinoid receptor and non-receptor signalling pathways, cannabinoids show specific cytotoxicity against tumour cells, while protecting healthy tissue from apoptosis. Cannabinoids also display potent anticancer activity against tumour xenografts, including tumours that express high resistance to standard chemotherapeutics.
Nebula was first introduced by Paradise Seeds back in 1996 and has won several different Cannabis Cup awards over the years and still to this day sits in a different galaxy to many of the other varieties of Cannabis seeds released into the market over the years since.
Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis
Cannabis-based medicines (CBMs) may offer relief from symptoms of disease; however, their additional cost needs to be considered alongside their effectiveness. We sought to review the economic costs and benefits of prescribed CBMs in any chronic illness, and the frameworks used for their economic evaluation. Prescribed CBMs are a potentially cost-effective add-on treatment for MS spasticity; however, this evidence is uncertain. Further investment in randomised trials with in-built economic evaluations is warranted for a wider range of clinical indications.
Lemon Skunk (DNA Genetics): A true aroma sensation super-packed with Limonene Words & Pics: Green Born Identity – G.B.I.
or many growers and smokers alike, fruity strains are the pinnacle of cannabis enjoyment. It’s absolutely amazing how versatile the cannabis plant is when it comes to producing different distinct fruit flavours such as lemon, orange, tangerine, grapefruit, blueberry, strawberry, pineapple or mango.
Parent use of cannabis for intractable pediatric epilepsy: Everyday empiricism and the boundaries of scientific medicine
Cannabis is an increasingly sought-after remedy for US children with intractable (biomedically uncontrollable) epilepsy. However, like other complementary-alternative medicine (CAM) modalities, and particularly as a federally illegal, stigmatised substance, it is unsanctioned by mainstream medicine. Parents are largely on their own when it comes to learning about, procuring, dispensing, and monitoring treatments. Exploring how they manage is crucial to better assist them. Implications for understanding the boundaries of science are explored, as are norms for parent agency as ill children’s care managers, radicalisation among people affected by contested illnesses, and the future of ‘medical marijuana.’
“If you love to smoke, grow S.A.G.E.!” – said famous cannabis scientist Robert Connell Clarke about S.A.G.E. twelve years ago when this strain came out. Well, not many, not to say no other, strains get such a testimony from the world’s leading cannabis expert, and Rob Clarke certainly wouldn’t have staked his good name for a mediocre strain.